Effects of fasudil in patients with high-altitude pulmonary hypertension
نویسندگان
چکیده
منابع مشابه
Effects of fasudil in patients with high-altitude pulmonary hypertension.
REFERENCES 1 Oster ME, Riehle-Colarusso T, Correa A. An update on cardiovascular malformations in congenital rubella syndrome. Birth Defects Res A Clin Mol Teratol 2010; 88: 1–8. 2 Taylor DM. Maternal rubella and pulmonary arterial stenoses. Br Med J 1964; 1: 1131. 3 Ellis JG, Kuzman WJ. Pulmonary artery stenosis, a frequent part of the congenital rubella syndrome. Calif Med 1966; 105: 435–439....
متن کاملHigh-altitude pulmonary hypertension.
High-altitude pulmonary hypertension (HAPH) is a specific disease affecting populations that live at high elevations. The prevalence of HAPH among those residing at high altitudes needs to be further defined. Whereas reduction in nitric oxide production may be one mechanism for the development of HAPH, the roles of endothelin-1 and prostaglandin I₂ pathways in the pathogenesis of HAPH deserve f...
متن کاملEvaluation of Pulmonary Hypertension In First Degree Relatives Of Patients With Primary Pulmonary Hypertension
Background: Pulmonary hypertension (PH) was defined for the first time in 1951 as primary pulmonary hypertension (PPH). Some studies emphasized on the role of genetics in the development of pulmonary hypertension in family members of affected patients. So, in this study we evaluated the prevalence of pulmonary hypertension in first degree family of patients with documented PPH. Methods: In thi...
متن کاملAcute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension.
P ulmonary hypertension (PH) is characterised by progressive elevation of pulmonary artery pressure and pulmonary vascular resistance. Pathohistological findings have demonstrated that PH is associated with abnormal vascular structures, including medial and/or intimal hypertrophy, concentric or eccentric intimal fibrosis, obstruction in the arterial lumen, and aneurysmal dilatation. Patients wi...
متن کاملPULMONARY HYPERTENSION Phosphodiesterase type 5 and high altitude pulmonary hypertension
Background: This study explored phosphodiesterase type 5 (PDE5) inhibition as a strategy for treating high altitude pulmonary arterial hypertension (HAPH). Methods: 689 subjects (313 men) of mean (SD) age 44 (0.6) years living above 2500 m were screened for HAPH by medical examination and electrocardiography, and 188 (27%) met the criteria for right ventricular hypertrophy. 44 underwent cardiac...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Respiratory Journal
سال: 2012
ISSN: 0903-1936,1399-3003
DOI: 10.1183/09031936.00095211